Title
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a phase iii, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Date Issued
01 December 2014
Access level
metadata only access
Resource Type
journal article
Author(s)
Weinblatt M.E.
Genovese M.C.
Ho M.
Hollis S.
Rosiak-Jedrychowicz K.
Kavanaugh A.
Millson D.S.
Wang M.
Van Der Heijde D.
Publisher(s)
John Wiley and Sons Inc
Abstract
Objective This phase III, 52-week study compared fostamatinib with placebo (for 24 weeks) in patients with active rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX) therapy.
Start page
3255
End page
3264
Volume
66
Issue
12
Language
English
OCDE Knowledge area
Reumatología
Farmacología, Farmacia
Scopus EID
2-s2.0-84912051613
PubMed ID
Source
Arthritis and Rheumatology
ISSN of the container
23265191
Sources of information:
Directorio de Producción Científica
Scopus